聚乙二醇干扰素(Peg-IFN)α-2a联合恩替卡韦(ETV)治疗慢性乙肝的疗效

Peginterferon (Peg-IFN) alpha-2a combined with entecavir cave (ETV) in the treatment of chronic hepatitis B

目的:探讨聚乙二醇干扰素(Peg-IFN)α-2a联合恩替卡韦(ETV)治疗慢性乙肝的疗效。方法:收治慢性乙肝患者88例,依照入院顺序将其分为对照组和研究组,各44例。对照组采用聚乙二醇干扰素治疗,研究组采用聚乙二醇干扰素联合恩替卡韦治疗。结果:研究组患者HBeAg转阴率、HBV-DNA转阴率、HBeAg/抗HBe血清转换率、ALT复常率及临床疗效明显优于对照组(P<0.05)。结论:针对慢性乙肝患者采用聚乙二醇干扰素联合恩替卡韦进行治疗,可有效提高临床治疗效果,且安全性较高。

Objective:To investigate the efficacy of peginterferon(Peg-IFN)alpha-2a combined with entecavir cave(ETV)in the treatment of chronic hepatitis B.Methods:88 patients with chronic hepatitis B were selecte,and they were divided into the control group and the study group with 44 cases in each group according to the order of admission.The control group was treated with peginterferon,and the study group was treated with peginterferon and entecavir.Results:The HBeAg negative rate,HBV-DNA negative rate,HBeAg/anti HBe seroconversion rate,ALT recurrence rate and clinical efficacy of the study group were significantly better than those of the control group(P<0.05).Conclusion:For patients with chronic hepatitis B,peginterferon combined with entecavir can effectively improve the clinical efficacy and safety.